Table 2 Baseline characteristics of coagulopathic and non-coagulopathic patients
Coagulopathic patients (n = 136) | Non-coagulopathic patients (n = 104) | P value | |
|---|---|---|---|
RBCs prior to trial drug, units (n) | 8.4 ± 1.6 (134) | 8.4 ± 1.4 (98) | 1.00 |
FFP prior to trial drug, ml (n) | 922 ± 627 (102) | 95 ± 178 (88) | <0.001 |
Platelets prior to trial drug, ml (n) | 126 ± 181 (128) | 0 ± 0 (100) | <0.001 |
Cryoprecipitate prior to trial drug, ml (n) | 28 ± 78 (135) | 0 ± 0 (104) | <0.001 |
FFP after trial drug to 48 hours, ml (n) | 1,596 ± 1,777 (102) | 1,499 ± 1,927 (88) | 0.72 |
Platelets after trial drug to 48 hours, ml (n) | 289 ± 341 (127) | 319 ± 432 (100) | 0.57 |
Cryoprecipitate after trial drug to 48 hours, ml (n) | 56 ± 151 (135) | 33 ± 121 (104) | 0.19 |
Injury severity score (n) | 30 ± 13 (131) | 26 ± 13 (104) | 0.02 |
Temperature, °C (n) | 35.1 ± 1.4 (92) | 35.2 ± 1.5 (62) | 0.68 |
Mean arterial pressure, mm Hg (n) | 76 ± 22 (132) | 74 ± 18 (101) | 0.45 |
pH (n) | 7.28 ± 0.11 (130) | 7.24 ± 0.12 (101) | 0.01 |
Hematocrit, percentage (n) | 25 ± 8 (104) | 28 ± 9 (83) | 0.02 |
aPTT, seconds (n) | 50 ± 25 (79) | 54 ± 30 (51) | 0.43 |
PT, seconds (n) | 19 ± 6 (90) | 21 ± 6 (58) | 0.05 |
Platelet count, × 109 (n) | 78 ± 45 (122) | 70 ± 47 (98) | 0.20 |
Fibrinogen, g/l (n) | 1.3 ± 0.7 (90) | 1.2 ± 1.2 (58) | 0.57 |
48-hour mortality, n (percentage) | 21 (15) | 20 (19) | 0.44 |
30-day mortality, n (percentage) | 32 (24) | 29 (28) | 0.44 |